Valeant Pharmaceuticals International, Inc. ( VRX) Q3 2010 Earnings Call November 4, 2010 8:00 AM EST Executives Laurie Little – IR Mike Pearson – CEO Rajiv De Silva – President and COO, Specialty Pharmaceuticals. Peggy Mulligan – CFO Analysts Randall Stanicky – Goldman Sachs Gregg Gilbert – Bank of America Merrill Lynch Marc Goodman – UBS Corey Davis – Jefferies Douglas Miehm – RBC Capital Markets Annabel Samimy – Stifel Nicolaus Lennox Gibbs – TD Securities Michael Tong – Wells Fargo Hari Sambasivam – National Bank Financial Graham Tanaka – Tanaka Capital Juan Sanchez – Ladenburg PresentationOperator
Good morning. My name is Amanda and I will be your conference operator today. At this time, I would like to welcome everyone to the Valeant third quarter 2010 earnings conference call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks there will be a question-and-answer session. (Operator Instructions). Thank you. Ms. Laurie Little, you may begin your conference. Laurie Little Good morning, and welcome, everyone to Valeant's third quarter 2010 financial results conference call. Joining us on the call today are Mike Pearson, Chief Executive Officer; Peggy Mulligan, Chief Financial Officer; and Rajiv De Silva, President and Chief Operating Officer of Specialty Pharmaceuticals. In addition to this live webcast, a copy of today's slide presentation can be found on our website under the Investor Relations section within the webcast event details. Before we begin, please turn your attention to the slide containing our cautionary statement regarding forward-looking statements. Certain statements made in this presentation and other statements made during this call and the Q&A session afterwards may constitute forward-looking statements.